Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial. - Kan XF; Liang B; Zhang XL; Yu L; Luo YC; Zhou S; Liu RB; Xu GH; Li HL; Liao ZY; Xiang H; Lu W; et al. (BMC medicine, 2025)